SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GLGC Gene Logic
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (194)4/22/2005 5:43:57 PM
From: Mike McFarland  Read Replies (1) of 360
 
<dcgn is capturing most of the development upside>
maybe that is built into the shares--dcgn's price
to book ratio is ten times glgc. Indeed, the
street gives a glgc enterprise valuation of
less than zero. How can chemical space be so vast
(I read that the other day) and yet glgc hasn't
yet found a way to generate some value?
Would a chemistry partner for glgc
be a better fit than a perlegen?

DCGN--is this development upside on drugs
for smallish populations?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News